Is Pfizer a yield trap? No way.

Pfizer's 7% dividend yield ranks among the highest in the healthcare sector, nearly triple the average of the S&P 500. The payout ratio has improved to 89% from over 100% in recent quarters, but ...

In early May 2026, Pfizer reported first-quarter revenue of US$14.45 billion and net income of US$2.69 billion, with earnings ...

Explore the exciting world of Pfizer (NYSE: PFE) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals versus peers. The company leads its peer group in EBITDA and revenue growth, ...

If you are wondering whether Pfizer's current share price properly reflects its long term potential, the recent share ...

Pfizer PFE reported stronger third-quarter results than we anticipated, largely due to significantly higher sales of covid-19 treatment Paxlovid, which also drove management to increase its top- and ...

Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted EPS down 18%. In the battle for Metsera’s obesity pipeline, Pfizer announced ...

Activist investment fund Starboard Value took at stake in Pfizer recently, hoping to change its course. Starboard claimed that a pair of former top managers were willing to act as advisors. Those ...